| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048635299 |
| P356 | DOI | 10.1007/S00401-014-1276-0 |
| P932 | PMC publication ID | 4059991 |
| P698 | PubMed publication ID | 24791927 |
| P5875 | ResearchGate publication ID | 262050375 |
| P50 | author | Peter Lichter | Q2076661 |
| Gudrun Fleischhack | Q92107761 | ||
| Carsten Dachsbacher | Q102839730 | ||
| Kerstin Kaulich | Q114726762 | ||
| Heyko Skladny | Q114726763 | ||
| Guido Reifenberger | Q30004009 | ||
| Stefan M. Pfister | Q39183179 | ||
| Volker Hovestadt | Q43153333 | ||
| Marc Remke | Q43153350 | ||
| David T. W. Jones | Q58388511 | ||
| Jörg Felsberg | Q66360667 | ||
| Michael D. Taylor | Q88072573 | ||
| André O von Bueren | Q88766377 | ||
| Andrey Korshunov | Q89166780 | ||
| Andreas Faldum | Q90049005 | ||
| Katja von Hoff | Q90355734 | ||
| Stefan Rutkowski | Q90355738 | ||
| Marcel Kool | Q90637389 | ||
| Martin Mynarek | Q90928955 | ||
| Tobias Goschzik | Q90928960 | ||
| Paul A Northcott | Q91826566 | ||
| P2093 | author name string | Torsten Pietsch | |
| Rene Schmidt | |||
| Friedrich Cremer | |||
| P2860 | cites work | Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification | Q24530153 |
| Molecular subgroups of medulloblastoma: the current consensus | Q24615271 | ||
| Dissecting the genomic complexity underlying medulloblastoma | Q24621907 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 | ||
| Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci | Q28236937 | ||
| beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 | ||
| DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies | Q28282708 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 | ||
| Mutations in SUFU predispose to medulloblastoma | Q34133729 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome--a new clinical perspective | Q34605276 | ||
| Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study | Q36025964 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma | Q36929844 | ||
| Medulloblastomics: the end of the beginning | Q37469904 | ||
| Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. | Q39875833 | ||
| Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas | Q40156627 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors | Q40795419 | ||
| Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays | Q43153279 | ||
| Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Q45120061 | ||
| Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas | Q45345260 | ||
| Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 | ||
| Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification | Q48194323 | ||
| TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. | Q54402731 | ||
| Adult medulloblastoma comprises three major molecular variants. | Q55463035 | ||
| Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. | Q55468802 | ||
| Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 137-149 | |
| P577 | publication date | 2014-05-04 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort | |
| P478 | volume | 128 |
| Q33665382 | A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience |
| Q90843167 | A little piece of mind: best practices for brain tumor intraoperative consultation |
| Q48116800 | Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. |
| Q58491122 | Brain Tumours |
| Q37688184 | CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways |
| Q38819030 | Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials |
| Q48138393 | Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors |
| Q39795085 | Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy |
| Q91719964 | DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas |
| Q52655770 | DNA methylation-based classification of central nervous system tumours. |
| Q50063187 | DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma |
| Q38836198 | Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells |
| Q55459405 | Extent of resection in medulloblastoma: time to reconsider? |
| Q36142459 | Genetic and molecular alterations across medulloblastoma subgroups |
| Q48361757 | Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas |
| Q92811055 | Human Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype |
| Q38629781 | Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. |
| Q91596369 | Medulloblastoma |
| Q54954567 | Medulloblastoma in the Molecular Era. |
| Q36493799 | Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? |
| Q50089784 | Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. |
| Q38791824 | Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm |
| Q64079587 | Medulloblastoma: optimizing care with a multidisciplinary approach |
| Q50604253 | Medulloblastoma: selecting children for reduced treatment. |
| Q37573700 | Molecular Classification of Medulloblastoma |
| Q39181104 | Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours |
| Q36367397 | Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. |
| Q47827397 | Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). |
| Q98191465 | Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma |
| Q37004219 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis |
| Q41989047 | Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases |
| Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
| Q91780113 | Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience |
| Q41969132 | Spatial heterogeneity in medulloblastoma |
| Q52097904 | Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells. |
| Q88800677 | The clinical importance of medulloblastoma extent of resection: a systematic review |
| Q37391485 | Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline |
Search more.